Podcast 29 Aug 2025A Finnish biotech is making progress on Parkinson’s disease with support from The Michael J. Fox Foundation Our guest this week is Antti Vuolanto, CEO of Herantis Pharma, and we discussed the science behind their approach, and the advantages and challenges of working in biotech in the Nordics. August 29, 2025 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
In Depth 14 May 2025 The stem cell race for Parkinson’s disease: Recent studies show significant promise Discover how stem cells could be used to treat Parkinson’s disease, as positive early-stage studies in the field show significant promise. May 14, 2025 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Sponsored by Collaborative Drug Discovery Inc. 25 Feb 2025 How a virtual company leveraged data to accelerate drug development for neurodegenerative diseases Find out how the virtual biotech company Libra Therapeutics leveraged data to accelerate drug development for neurodegenerative diseases. February 25, 2025 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 19 Sep 2024 Mitochondrial disease treatments: is a breakthrough on the horizon? Mitochondrial dysfunction is linked to many diseases. Discover how biotechs are developing mitochondrial disease treatments to address these diseases. September 19, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 Aug 2024 10 neuroscience biotech companies you should know about Learn more about nine of the top neuroscience biotech companies looking to develop treatments for difficult-to-treat neurological conditions. August 15, 2024 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 14 Aug 2024 CAR-T drugs and parkinsonism: a cause for concern? CAR-T therapies come with boxed warnings of serious neurotoxic side effects. Now, growing concerns over parkinsonism have led to a clinical trial halt. August 14, 2024 - 3 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 4 Jul 2024 Parkinson’s disease: biotech’s pursuit for more therapies Rigorous research aims to boost therapeutic options for people with Parkinson’s disease. What do biotechs have in store? July 4, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 May 2024 Stem cell therapy’s avant-garde: Eight companies leading the way Stem cell therapy has gained traction over the recent years and the market is growing, discover eight companies advancing the field. May 30, 2024 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 19 Jan 2024 Re-coding the brain: Is CRISPR capable of curing neurodegenerative diseases? Check out our latest article as we explore some of the latest research around using CRISPR technology to treat neurodegenerative diseases. January 19, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 15 Dec 2023Vaxxinity making vaccines to change the world Discover how Vaxxinity’s vaccine approach aims to democratize global health, potentially reshaping access to innovative treatments worldwide. December 15, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2023 Partnership to progress neurodegenerative disorder treatments IRBM, Rainwater Charitable Foundation (RCF, Fort Worth, Texas), a private family foundation, and Weill Cornell Medicine (based in New York) are starting a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. The collaboration brings together IRBM’s capabilities in drug discovery and […] July 13, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2023 NodThera first to show reduction in neuroinflammation with inflammasome inhibitor NodThera has announced positive, initial data from four subjects in the elderly volunteer stage of its phase Ib/IIa study evaluating the effects of its lead candidate NT-0796 on inflammatory and disease-specific biomarkers in the blood and cerebrospinal fluid (CSF). NodThera is a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. Alan […] July 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email